title: Do prophylactic antilymphocyte globulins (ALG and OKT3) improve renal transplant survival in recipient and donor high-risk groups?
authors.affiliation: Department of Surgery, University of California, Los Angeles 90024.
authors.forename: J M
authors.initials: JM
authors.lastname: Cecka
authors.forename: D
authors.initials: D
authors.lastname: Gjertson
authors.forename: P I
authors.initials: PI
authors.lastname: Terasaki
mesh_terms: D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002102:Cadaver; D005500:Follow-Up Studies; D006085:Graft Survival / Q000276:immunology*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D012042:Registries; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
chemical_list: D000961:Antilymphocyte Serum; D016853:Muromonab-CD3